Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo-controlled, double-blind, multicenter clinical trial

Clinical Cardiology

Volumn 19, Issue 5, 1996, Pages 409-412

  Fresco, Claudio ^a   Proclemer, Alessandro ^b   Pavan, Alessandro ^b   Buia, Gianfranco ^b   Vicentini, Alfredo ^b   Pavan, Daniela ^b   Morgera, Tullio ^b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b NONE

Author keywords

antiarrhythmic drugs; clinical trial; paroxysmal atrial fibrillation; propafenone

Indexed keywords

PROPAFENONE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART VOLUME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

EID: 0029788783     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190515     Document Type: Article

References (13)

1. Gajewski J, Singer RB: Mortality in an insured population with atrial fibrillation. J Am Med Assoc 1981;245:1540-1544
2. Petersen P. Godtfredsen J: Embolic complications in paroxysmal atrial fibrillation. Stroke 1988;19:622-626
3. Bolognesi R: The pharmacologic treatment of atrial fibrillation. Card Drug Ther 1991;5:617-628
4. Bracchetti D, Palmieri M, on behalf of the PAFIT-1 Group: Safety and efficacy of propafenone i.v. in conversion of paroxysmal atrial fibrillation of recent onset. Circulation 1992;86(suppl 1):664
5. Kerber RE, Martins JB, Kienzle MG: Energy, current, and success in defribrillation and cardioversion. Clinical studies using an automated impedance-based method of energy adjustment. Circulation. 1988;77:1038-1046
6. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, van Hemel NM, Lie KI: The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-1727
7. Anderson JL, Jolivette DM, Fredell PA: Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 1988;62:62D-66D
8. Falk RH: Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:141-150
9. Capucci A, Boriani G, Botto GL, Falcone C, Rubino I, Lenzi T, Trisolino G, Binetti N, Sanguinetti M, Magnani B: Conversion of recent onset atrial fibrillation: A controlled study on 163 patients evaluating the efficacy of a single oral loading dose of propafenone or flecainide (abstr). Eur Heart J 1993;14(suppl):164
10. Connolly SJ, Hoffert DL: Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819
11. Pritchett ELC, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544
12. CAST Investigators: Preliminary Report: Effect of flecainide and encainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412
13. Farahi JJ, Singh BN: Atrial fibrillation: Prognostic significance and therapeutic implications in Prognosis and Risk Assessment in Cardiovascular Disease (Eds. Kapoor AS, Singh BN). New York: Churchill Livingstone, 1993:333-358